Censis Technologies and Cantel Medical Enter Into Partnership

To Develop Differentiated Endoscope Reprocessing Software Solution

Censis Technologies and Cantel Medical have entered into a new long-term partnership to combine Cantel’s leading infection prevention endoscope reprocessing workflow portfolio with the surgical asset management and instrument tracking solutions from Censis.

The new enhanced, co-branded software solution will combine the CANEXIS™ Integrated Workflow Solution for Endoscopy from Cantel with Censis’ CensiTrac™ surgical asset management software to create the leading instrument reprocessing and scope tracking software available to the market. Leveraging Censis’ strengths in software development, cloud-based technology, and professional services and support with the leading position in endoscope reprocessing and infection prevention from Cantel, the combined solution will support endoscopy customers with best-in-class quality management tools, providing peace of mind and confidence that their facility is executing best practices to support patient safety and infection prevention.

This enhanced integrated workflow solution is a key tool in the fight to avoid the spread of infection, while helping to protect patients and reducing the economic burden on facilities, while also supporting improved efficiency and understanding of the use of critical medical devices in healthcare facilities. In today’s environment, efficiency and process consistency are increasingly critical to the day-to-day and long-term success of infection prevention, and this software application is an important resource for helping to ensure a consistent repeatable standard of care and process at each facility.

Healthcare-associated infections (HAIs) are a complex and persistent issue in healthcare facilities. Each year, approximately 1.7 million HAIs occur, and outbreaks also pose a severe economic burden to the health system, with the total direct, indirect, and nonmedical social costs of HAIs to hospitals ranging from US$96 billion to $147 billion.1

Randy Smith, CEO, Censis Technologies said, “The relationship with Cantel will expand Censis’ leadership in surgical asset management and tracking solutions by further introducing innovative SaaS-based technology for the reprocessing of endoscopes. We are excited that the combined efforts of these two organizations will provide our customers with opportunities to improve patient safety, workflow optimization, and analytics.”

“We are thrilled to be partnering with Censis on this critical endeavor,” said Michael Spicer, President, Medical Business Unit at Cantel. “At Cantel, we strive to ensure our Complete Circle of Protection includes best-in-class offerings for our customers and patients, and by partnering with Censis, we are taking the next step toward providing greater efficiency, protection, and analytics to allow our customers to maximize their practice workflow while providing solutions designed to improve the safety and protection of their patients.”

Within the United States, users of the current CANEXIS™ Software can look forward to robust coverage, including implementation, upgrades, and technical support, as their service is enhanced through the co-brand partnership.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version